[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100592424":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":37,"responsibleParty":55,"collaborators":59,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":65,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":20,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":87,"whyStopped":20,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Ottawa Hospital Research Institute","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"**Contrast-Enhanced Mammography for Supplemental Breast Cancer Screening**","EXPERIMENTAL","This arm involves participants undergoing Contrast-Enhanced Mammography (CEM) as a supplemental screening method for breast cancer. CEM combines standard mammography with iodinated contrast medium to improve lesion visualization and tumor detection, particularly in women with dense breast tissue. Participants will receive CEM during a single visit at the Rose Ages Breast Health Centre, and their results will be evaluated for cancer detection, abnormal interpretation rates, and biopsy outcomes.",[13],"Diagnostic Test: Contrast-Enhanced Mammography (CEM)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIAGNOSTIC_TEST","Contrast-Enhanced Mammography (CEM)","The intervention involves the use of contrast-enhanced mammography (CEM) to supplement standard mammography for breast cancer screening. This method utilizes iodinated contrast medium to enhance the visualization of breast lesions by assessing tumor neovascularization. CEM will be offered to women with dense breast tissue who are currently awaiting supplemental ultrasound screening. It is designed to be performed in conjunction with regular mammography, offering a more efficient and cost-effective alternative to MRI, with comparable sensitivity in detecting breast cancer. Participants will undergo the CEM procedure in a single visit, allowing for reduced wait times and improved detection rates compared to traditional methods. The procedure is well-tolerated, with minimal side effects, and provides a quicker and more accessible option for supplemental breast cancer screening.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Dr. Jean Seely Principal Investigator,, MD FRCPC","PRINCIPAL_INVESTIGATOR",[26,32],{"name":27,"role":28,"phone":29,"phoneExt":30,"email":31},"Dr. Jean Seely Department of Radiology, Radiation Oncology, MD, FRCPC, MD, FRCPC","CONTACT","613-737-8899","Ext. 73665","jeseely@toh.ca",{"name":33,"role":28,"phone":34,"phoneExt":35,"email":36},"Dr. Betty Anne Schwarz, Director of Research Services, DProf, RN BA MSc","613-798-5555","Ext. 17522","baschwarz@ohri.ca",[38],{"facility":39,"status":20,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"The Ottawa Hospital","Ottawa","Ontario","K1H 9L6","Canada","CA",{"type":46,"coordinates":47},"Point",[48,49],-75.69812,45.41117,{"lat":49,"lon":48},[52],{"name":53,"role":28,"phone":20,"phoneExt":20,"email":54},"Dr. Jean Seely Principal Investigator, MD FRCPC","jeseely@toh.on.ca",{"type":56,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"SPONSOR_INVESTIGATOR","Jean Seely","Physician Medical Imaging",[60],{"name":61,"class":62},"Bayer Healthcare Pharmaceuticals, Inc.\u002FBayer Schering Pharma","INDUSTRY","100592424","contrast-enhanced-mammography-in-women-with-a-personal-history-of-breast-cancer-and-dense-breast-tissue-benefit-100592424",false,"NCT06993246","Contrast-enhanced Mammography in Women With a Personal History of Breast Cancer and Dense Breast Tissue: Benefit?","Does Supplemental Contrast-enhanced Mammography Have a Benefit in Women With a Personal History of Breast Cancer and Dense Breast Tissue? A Prospective Cohort Study.","CEM","Inclusion Criteria:\n\n* Women presenting at Rose Ages Breast Health Center, who are currently waiting for supplemental screening Ultrasound, according to pre-established guidelines at TOH for supplemental screening.\n* Women ages 50-69 years of age\n* Those willing to participate in the study, sign an informed consent and undergo IV iodinated contrast injection\n* Women with dense breasts (category C or D) and normal mammograms (BI-RADS 1 or 2)\n* No evidence of renal disease\n\nExclusion Criteria:\n\n* Patients with renal insufficiency (reduced eGFR \\\u003C20ml\u002Fmin)\n* Previous allergic reactions to Iodine-based contrast.\n* Prior contrast allergy (CT contrast)\n* Thyroid Disease","FEMALE","50 Years","69 Years",{"count":75,"type":76},50,"ESTIMATED","INTERVENTIONAL",[79],"NA","This study aims to assess the effectiveness of Contrast-Enhanced Mammography (CEM)as an alternative to traditional ultrasound for breast cancer screening in women with dense breasts and a personal history of breast cancer. CEM combines standard mammography with a contrast agent to better detect tumors, particularly in women with dense tissue where traditional mammograms may miss signs of cancer. The study will compare CEM with ultrasound and MRI to determine its accuracy in detecting cancer, reduce wait times for screening, and provide a more affordable option than MRI. Women who participate will have their screening done in one visit, improving convenience and access. The study will track cancer detection rates, biopsy results, and patient satisfaction over two years to evaluate the benefits of CEM for early breast cancer detection.",[82],"Breast Cancer",[84,85,86],"Mammography screening","Contrast-Enhanced Mammography","Dense breasts","NOT_YET_RECRUITING","2025-05-23",{"date":90,"type":91},"2025-05-28","ACTUAL",{"date":93,"type":76},"2025-09-15",{"date":95,"type":76},"2028-09-30",{"name":57,"class":6},1]